Peter Duesberg and David Rasnick


We thank Fred Cline, Harry Haverkos, Phil Johnson, Serge Lang, Russell Schoch and Richard Strohman for information and advice, and Siggi Duesberg for review and preparation of the manuscript. This investigation was supported in part by the Council for Tobacco Research, USA, and private donations from Robert Leppo, San Francisco, Tom Boulger, Los Angeles, Carol J. Wilhelmy, San Mateo, the participants of the Anthony Robbins Life Mastery University 1995 and 1996, Robbins Research International, San Diego, and a foundation that prefers to remain anonymous.


1. Moberg CL, Cohn ZA. Rene Jules Dubos. Sci Am 1991; 264: 66-74.

2. Feynman R. Surely you must be joking, Mr. Feynman. Bantam, New York, 1985.

3. Centers for Disease Control and Prevention. U.S. HIV and AIDS cases reported through December 1995. HIV/AIDS Surveillance Report 1995; 7: 1-39.

4. Institute of Medicine, National Academy of Sciences. Confronting AIDS. National Academy Press, Washington, DC, 1986.

5. Institute of Medicine. Confronting AIDS—Update 1988. National Academy Press, Washington, DC, 1988.

6. Adams J. AIDS: The HIV Myth. St. Martin’s Press, New York, 1989.

7. Hodgkinson N. AIDS: the failure of contemporary science. Fourth Estate, London, UK, 1996.

8. Rothman S. Remarks on sex, age and racial distribution of Kaposi’s sarcoma and on possible pathogenic factors. Acta Unio Int Contra Cancrum 1962; 18: 326.

9. Oettle AG. Geographical and racial differences in the frequencies of Kaposi’s sarcoma as evidence of environmental or genetic causes. Acta Unio Int Contra Cancrum 1962; 18: 330-362.

10. Springer Verlag. 50 Jahre Springer - 50 Jahre Zeitzeuge. Axel Springer Verlag, Hamburg, 1996.

11. Duesberg P. Inventing the AIDS Virus. Regnery Publishing Inc., Washington, 1996.

12. Horton R. Truth and heresy about AIDS. The New York Review 1996; 43: 14, 16-20, May 23.

13. Institute of Medicine. Confronting AIDS. National Academy Press, Washington, DC, 1986.

14. Anonymous (eds.) The relationship between Human Immunodeficiency Virus and the Acquired Immunodeficiency Syndrome (1996), National Institute for Allergy & Infectious Diseases, Bethesda, MD, .

15. Altman LK. Researchers believe AIDS virus is found. New York Times (New York) 1984: C1, C3, April 24.

16. Cohen J. The Duesberg Phenomenon. Science 1994; 266: 1642-1649.

17. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mort Weekly Rep 1992; 41(No. RR17): 1-19.

18. Duesberg PH. Infectious AIDS stretching the germ theory beyond its limits. Int Arch Allergy Immunol 1994; 103: 131-142.

19. Auerbach DM, Darrow WW, Jaffe HW, Curran JW. Cluster of cases of the Acquired Immune Deficiency Syndrome patients linked by sexual contact. Am J Med 1984; 76: 487-492.

20. Bregman DJ, Langmuir AD. Farr’s law applied to AIDS projections. J Am Med Assoc 1990; 263: 50-57.

21. National Commission on AIDS. The Twin Epidemics of Substance Use and HIV. July 1991;

22. Duesberg P. Duesberg’s questions. C&EN 1996; 4, 40.

23. Duesberg P. Is HIV the cause of AIDS? (letter). Lancet 1995; 346: 1371-1372.

24. Duesberg P. Foreign-protein-mediated immunodeficiency in hemophiliacs with and without HIV. Genetica 1995; 95: 51-70.

25. Duesberg P. How much longer can we afford the AIDS virus monopoly?, in AIDS: virus or drug-induced?, P. Duesberg (eds.) Kluwer, Dordrecht, Netherlands, 1996; 241-270.

26. Duesberg PH. AIDS acquired by drug consumption and other noncontagious risk factors. Pharmacology & Therapeutics 1992; 55: 201-277.

27. Drotman DP, Peterman TA, Friedman-Kien AE. Kaposi’s sarcoma. How can epidemiology help find the cause? Dermatoepidemiology 1995; 13: 575-582.

28. Bennett A, Sharpe A. AIDS fight is skewed by federal campaign exaggerating risks. Wall Street Journal 1996: 1, A6, May 1.

29. Krieger L. 1 in 300 U.S. adults infected, says report. SF Examiner (San Francisco) 1996: A8, July 7.

30. Simmonds P, Balfe P, Peutherer JF, Ludlam CA, Bishop JO, Leigh-Brown AJ. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol 1990; 64: 864-872.

31. Duesberg PH, Bialy H. Duesberg and the right of reply according to Maddox-Nature, in AIDS: virus- or drug induced?, P. H. Duesberg (eds.) Kluwer Academic Publishers, Dordrecht/Boston/London, 1996; 111-125.

32. Craddock M. HIV: Science by press conference, in AIDS: virus- or drug induced?, (eds.) Kluwer, Dordrecht, Netherland, 1996; 127-130.

33. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid Turnover of Plasma Virions and CD4 Lymphocytes in HIV-1 Infection. Nature 1995; 373: 123-126.

34. Maddox J. Duesberg and the new view of HIV. Nature 1995; 373: 189.

35. Duesberg P, Horton R. The AIDS Heresy: an exchange. The New York Review 1996; 43: 51, August 8.

36. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990; 335: 123-128.

37. Haverkos HW, Drotman DP, Hanson D. Surveillance for AIDS-related Kaposi’s sarcoma (KS): update. NIDA/CDC, Rockville, MD/Atlanta, GA 1994; May.

38. Duesberg P. Commentary: non-HIV hypotheses must be studied more carefully. BMJ 1996; 312: 210-211.

39. Lockemann U, Wischhusen F, Pueschel K, et al. Vergleich der HIV-1-Praevalenz bei Drogentodesfaellen in Deutschland sowie in verschiedenen europaeischen Grosstaedten (Stand: 31. 12. 1993). AIDS Forschung 1995; 10: 253-256.

40. Brettle RP. Clinical features of drug use and drug use related to HIV. Int J STD & AIDS 1996; 7: 151-165.

41. Hayes T, Altman R, Akili-Obika A, Buehler JW, Costa SJ, Beil JK, Moore LG, Massey JW, Williams NM. HIV-related deaths from selected infectious diseases among persons without AIDS in New Jersey. Journal of Acquired Immune Deficiency Syndromes 1994; 7: 1074-1078.

42. Kitange HM, Machibya H, Black J, Mtasiwa DM, Masuki G, Whiting D, Unwin N, Moshiro C, Klima PM, Lewanga M, Alberti KGMM, McLarty D, for adult morbidity and mortality project. Outlook for survivors of childhood in sub-Saharan Africa: adult mortality in Tanzania. BMJ 1996; 312: 216-220.

43. Peterman TA, Stoneburner RL, Allen JR, Jaffe HW, Curran JW. Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. JAMA 1988; 259: 55-58.

44. Jacquez JA, Koopman JS, Simon CP, Longini Jr. IM. Role of the primary infection in epidemics of HIV infection in gay chorts. J Acquired Immune Deficiency Syndromes 1994; 7: 1169-1184.

45. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, Jimenez E, O’Neill E, Bazin B, Delfraissy J-F, Culnane M, Coombs R, Elkins M, Moye J, Stratton P, Balsley J, Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 With Zidovudine Treatment. New Engl J Med 1994; 331: 1173-1180.

46. Duesberg PH. Retroviruses as carcinogens and pathogens: expectations and reality. Cancer Res 1987; 47: 1199-1220.

47. Duesberg PH. HIV and AIDS. Science 1993; 260: 1705.

48. Duesberg PH. The HIV gap in national AIDS statistics. Biotechnology 1993; 11: 955-956.

49. Cone RW, Hackman RC, Huang M-LW, Bowden RA, Meyers JD, Metcalf M, Zeh J, Ashley R, Corey L. Human herpesvirus 6 in lung tissue from patients with pneumonia after bone marrow transplantation. NEnglJMed 1993; 329: 156-161.

50. Mims C, White DO. Viral Pathogenesis and Immunology. Blackwell Scientific Publications, Oxford, 1984.

51. Drug Strategies. Keeping score; What We Are Getting for Our Federal Drug Control Dollars. Drug Strategies, Washington DC, 1995.

52. Bureau of Justice Statistics. Drugs, crime, and the justice system. U.S. Dept. of Justice, Washington DC, 1992.

53. Clinton W, The White House. The National Drug Control Strategy: 1996. The White House, Washington DC, 1996.

54. Courtwright DT. Dark Paradise: opiate addiction in America before 1940. Harvard University Press, Cambridge, MA, 1982.

55. Jonnes J. Hep-cats, narcs, and pipe dreams. Scribner, New York, 1996.

56. Haverkos HW, Dougherty J. Health hazards of nitrite inhalants. Am J Med 1988; 84: 479-482.

57. Siegel R. New pattenrs of cocaine use: changing doses and routes, in Cocaine use in America: epidemiologic and clinical perspectives, N. Kozel and E. Adams (eds.) NIDA Research Monographs, Washington DC, 1985;

58. Schuster C. Cocaine use in America: epidemiological and clinical perspectives, in NIDA Research Monograph Series, NIDA US Department HHS (eds.) US Dept. HHS, 1985; v.

59. Kozel NJ, Adams EH. Epidemiology of drug abuse: An overview. Science 1986; 234: 970-974.

60. Meddis SV. Heroin use said to near crisis level. USA Today (Arlington) 1994: 1, 3A, May 25.

61. U.S. Department of Health & Human Services. Annual Medical Examiner data. Data from the Drug Abuse Warning Network (DAWN) 1994; 1-82, 1994.

62. Office of National Drug Control Policy. Drugs & Crime Data. Drugs & Crime Clearinghouse 1996; July 1996.

63. Perlman D. Cocaine Emergencies Hit Record. SF Chronicle (San Francisco) 1996: A1, A9, May 1.

64. Bureau of Justice Statistics (eds.) Catalog of Federal Publications on Illegal Drug and Alcohol Abuse (1991), U.S. Department of Justice, Washington D.C., .

65. Flanagan TJ, Maguire K. Sourcebook of Criminal Justice Statistics (1989)—Bureau of Justice Statistics NCJ-124224. U.S. Department of Justice, U.S. Government Printing Office, Washington, DC, 1989.

66. Anderson W. Drug Smuggling. U. S. General Accounting Office, Washington, DC, 1987.

67. Schnoll SH, Karrigan J, Kitchen SB, Daghestani A, Hansen T. Characteristics of cocaine abusers presenting for treatment, in Cocaine use in America: epidemiologic and clinical perspectives, NIDA US Dept. HHS (eds.) US Dept. HHS, 1985; 171-181.

68. Gettman J. Heroin Returning to Center Stage. High Times 1994; 23, December.

69. Smith RJ. U.S. Is Losing War on Drugs, Analysts Say. San Francisco Chronicle (SF) 1995: A1, A9, July 10.

70. Evenson L, Whiting S. Heroin’s in Fashion--and Death Statistics Prove It. San Francisco Chronicle (San Francisco) 1996: A1-A8, Jul 30.

71. Sadownick D. Kneeling at the Crystal Cathedral. Genre 1994; 40-45, 86-90, December/January 1994.

72. Rotello G. A deal with the devil. The Advocate 1996; 96, October, 15.

73. Russell S. ‘Speed’ Hospitalizations Soar. SF Chronicle (San Francisco) 1996: A13, A15, July 2.

74. Drug Strategies. Keeping Score. Keeping Score 1996; 1-33.

75. Wallace B. ‘Speed’ Abusers Need More and More. SF Chronicle (San Francisco) 1996: A2, May 31.

76. Mann C. Poppers ... high time to think again. Continuum 1995; 3: 10,

77. Young I. Hell Bent ... or Heavenly Scent? Continuum 1995; 3: 22-25,

78. Bethell T. AIDS and Poppers, in AIDS: Virus- or Drug Induced?, P. Duesberg (eds.) Kluwer Academic Publishers, Dordrecht, 1996; 315-323.

79. San Francisco Department of Public Health, Lesbian & Gay Substance Abuse Planning Group. Lesbian, Gay and Bisexual Substance Abuse Needs Assessment. 1991, August;

80. Ascher MS, Sheppard HW, Winkelstein Jr W, Vittinghoff E. Does drug use cause AIDS? Nature 1993; 362: 103-104.

81. Haverkos HW, Drotman DP. NIDA technical review: nitrite inhalants. Biomedicine & Pharmacotherapy 1996; 50: 228-230.

82. Fietz M. Haschisch an der Spitze; SPD: Mildere Strafen fuer Drogenhaendler. Die Welt 1997; pp. 1,2, Jan. 8.

83. Rauschgiftbilanz 1994. Starke Nachfrage nach synthetischen Drogen. Deutsches Aerzteblatt 1995; 92: C-422.

84. AIDS-Forschung. AIDS Zentrum im Robert Koch Institut. 120. Bericht des AIDS-Zentrums im Robert-Koch-Institut über aktuelle epidemiologische Daten. AIDS-Forschung 1996; 11: 47-56.

85. U.S. Department of Health & Human Services. Annual emergency department data 1993. Data from the Drug Abuse Warning Network (DAWN) 1993; 81-110,

86. Stoneburner RL, Des Jarlais DC, Benezra D, Gorelkin L, Sotheran JL, Friedman SR, Schultz S, Marmor M, Mildvan D, Maslansky R. A larger spectrum of severe HIV-I-related disease in intravenous drug users in New York City. Science 1988; 242: 916-919.

87. Alcabes P, Schoenbaum EE, Klein RS. Correlates of the rate of decline of CD4+ lymphocytes among injection drug users infected with the human immunodeficiency virus. American Journal of Epidemiology 1993; 137: 989-1000.

88. Alcabes P, Munoz A, Vlahov D, Friedland G. Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users. AIDS Epidemiology and Pharmacology 1994; 4: 17-26.

89. Des Jarlais D, Friedman S, Marmor M, Cohen H, Mildvan D, Yancovitz S, Mathur U, El-Sadr W, Spira TJ, Garber J. Development of AIDS, HIV seroconversion, and potential cofactors for T4 cell loss in a cohort of intravenous drug users. AIDS 1987; 1: 105-111.

90. Novick DM, Ochshorn M, Ghali V, Croxson TS, Mercer WD, Chiorazzi N, Kreek MJ. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. The Journal of Pharmacologyt and Experimental Therapeutics 1989; 250: 606-610.

91. Margolick JB, Munoz A, Vlahov D, Solomon L, Astemborski J, Cohn S, Nelson KE. Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection. Journal of the American Medical Association 1992; 267: 1631-1636.

92. Margolick JB, Munoz A, Vlahov D, Astemborski J, Solomon L, He X-Y, Nelson KE, Saah AJ. Direct comparison of the relationship between clinical outcome and change in CD4+ lymphocytes in human immunodeficiency virus-positive homosexual men and injecting drug users. Archives of Internal Medicine 1994; 154: 869-875.

93. Galli M, Lazzarin A, Saracco A, Balotta C, Castagna A, Negri C, Ridolfo AL, Uberti-Foppa C, Corbellino M, Moroni M. Clinical and immunological aspects of HIV infection in drug addicts. Clinical Immunology and Immunopathology 1989; 50: S166-S176.

94. Mirken B. Everything you always wanted to know about poppers; the gay drug is still here despite a ban, and so is the controversy. San Francisco Frontiers Newsmagazine 1995; 14: 16-19, July 20.

95. St. Angelo M. Duesberg’s Questions About HIV/AIDS Merit Answers. Windy City Times 1996: 12, April 11.

96. Lauritsen J. NIDA meeting calls for research into the poppers-Kaposi’s sarcoma connection, in AIDS: Virus- or Drug Induced?, P. H. Duesberg (eds.) Kluwer Academic Publishers, Dordrecht, 1996; 325-330.

97. Lauritsen J. The AIDS War. Asklepios (Pagan Press), New York, 1993.

98. Shilts R. And the Band Played On. St. Martin’s Press, New York, 1987.

99. Ineichen H. Ausgeschnüffelt? aK (Switzerland) 1996; 5: 18-19, October November.

100. Ostrow DG. Substance abuse and HIV infection. Psychiatric Manifestations of HIV Disease 1994; 17: 69-89.

101. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. Long-term HIV-1 infection without immunologic progression. AIDS 1994; 8: 1123-1128.

102. Veugelers PJ, Page KA, Tindall B, Schechter MT, Moss AR, Winkelstein WW, Cooper DA, Craib KJP, Charlebois E, Coutinho RA, Van Griensven GJP. Determinants of HIV disease progression among homsexual men registered in the tricontinental seroconverter study. American Journal of Epidemiology 1994; 140: 747-758.

103. Kaslow RA, Blackwelder WC, Ostrow DG, Yerg D, Palenicek J, Coulson AH, Valdiserri RO. No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive individuals. J Am Med Assoc 1989; 261: 3424-3429.

104. Ostrow DG, Beltran ED, Joseph JG, DiFranceisco W, Wesch J, Chmiel JS. Recreational drugs and sexual behavior in the Chicago MACS/CCS cohort of homosexually active men. Journal of Substance Abuse 1993; 5: 311-325.

105. Schechter MT, Craib KJP, Montaner JSG, Le TN, O'Shaughnessy MV, Gelmon KA. Aetiology of AIDS. Lancet 1993; 341: 1222-1223.

106. Lau RKW, Jenkins P, Caun K, Forster SM, Weber JN, McManus TJ, Harris JRW, Jeffries DJ, Pinching AJ. Trends in sexual behaviour in a cohort of homosexual men: a 7 year prospective study. International Journal of STD & AIDS 1992; 3: 267-272.

107. Gibbons J. Drugs & Us. Gay Times (London) 1996; 17-37, September.

108. McManus TJ, Starrett LA, Harris JRW. Amyl Nitrite Use by Homosexuals. Lancet 1982; i: 503.

109. Lauritsen J. NIH reconsiders nitrites' link to AIDS. Biotechnology 1994; 12: 762-763.

110. Haverkos HW, Drotman DP. NIDA Technical Review: Nitrite Inhalants. NIDA, Washington, D.C & CDC, Atlanta, GA 1995; unpublished.

111. Jaffe HW, Choi K, Thomas PA, Haverkos HW, Auerbach DM, Guinan ME, Rogers MF, Spira TJ, Darrow WW, Kramer MA, Friedman SM, Monroe JM, Friedman-Kien AE, Laubenstein LJ, Marmor M, Safai B, Dritz SK, Crispi SJ, Fannin SL, Orkwis JP, Kelter A, Rushing WR, Thacker SB, Curran JW. National case-control study of Kaposi's sarcoma and Pneumocystis carinii pneumonia in homosexual men: Part 1, Epidemiologic results. Ann Intern Med 1983; 99: 145-151.

112. Darrow WW, Echenberg DF, Jaffe HW, O'Malley PM, Byers RH, Getchell JP, Curran JW. Risk factors for human immunodeficiency virus (HIV) infections in homosexual men. Am J Publ Health 1987; 77: 479-483.

113. Lifson AR, Darrow WW, Hessol NA, O'Malley PM, Barnhart JL, Jaffe HW, Rutherford GW. Kaposi's sarcoma in a cohort of homosexual and bisexual men: epidemiology and analysis for cofactors. Am J Epidemiol 1990; 131: 221-231.

114. Duesberg PH. Can epidemiology determine whether drugs or HIV cause AIDS? AIDS-Forschung 1993; 12: 627-635.

115. Ellison BJ, Downey AB, Duesberg PH. HIV as a surrogate marker for drug-use: a re-analysis of the San Francisco Men's Health Study, in AIDS: virus- or drug induced?, P. H. Duesberg (eds.) Kluwer Academic Publishers, Dordrecht, The Netherlands, 1996; 97-104.

116. Schechter MT, Craib KJP, Gelmon KA, Montaner JSG, Le TN, O'Shaughnessy MV. HIV-1 and the aetiology of AIDS. Lancet 1993; 341: 658-659.

117. Bacellar H, Munoz A, Miller EN, Cohen BA, Besley D, Selnes OA, Becker JT, McArthur JC. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology 1994; 44: 1892-1900.

118. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ. Striatal dopamine nerve terminal markers in human, chronic metamphetamine users. Nature Medicine 1996; 2: 699-703.

119. Achard C, Bernard H, Gagneux C. Action de la morphine sur les proprietes leucocytaires; leuco-diagnostic du morphinisme. Bulletin et Memoires de la Societe Medicale des Hopitaux de Paris 1909; 28, 3rd Series: 958-966.

120. Pillari G, Narus J. Physical effects of heroin addiction. Am J Nursing 1973; 73: 2105-2109.

121. Lerner WD. Cocaine abuse and acquired immunodeficiency syndrome: tale of two epidemics. Am J Med 1989; 87: 661-663.

122. Layon J, Idris A, Warzynski M, Sherer R, Brauner D, Patch O, McCulley D, Orris P. Altered T-lymphocyte subsets in hospitalized intravenous drug abusers. Arch Intern Med 1984; 144: 1376-1380.

123. Larrat PE, Zierler S. Entangled epidemics: cocaine use and HIV disease. J Psychoactive drugs 1993; 25: 207-221.

124. Pillai R, Nair BS, Watson RR. AIDS, drugs of abuse and the immune system: a complex immunotoxicological network. Arch Toxicol 1991; 65: 609-617.

125. Mientjes GHC, van Ameijden EJC, Weigel HM, van den Hoek JAR, Countinho RA. Clinical symptoms associated with seroconversion for HIV-1 among misusers of intravenous drugs: comparison with homosexual seroconverters and infected and non-infected intravenous drug misusers. BMJ 1993; 306: 371-373.

126. Wesson D, Smith D. Cocaine: treatment perspectives, in Cocaine Use in America: epidemiologic and clinical perspectives, N. Kozel and E. Adams (eds.) NIDA US Dept. HHS, Washington, DC, 1985;

127. Muñoz A, Vlahov D, Solomon L, Margolick JB, Bareta JC, Cohn S, Astemborski J, Nelson KE. Prognostic indicators for development of AIDS among intranvenous drug users. JAIDS 1992; 5: 694-700.

128. Clair DA. Drug treatment specialist of the Federal Bureau of Prisons, Greenville IL. personal communication August 1996;

129. Weil A, Rosen W. Chocolate and morphine. Houghton Mifflin Co., Boston, 1983.

130. Haverkos HW, Dougherty JA (eds.) Health Hazards of Nitrite Inhalants (1988), US. Dept. Health & Human Services, Washington, DC, .

131. Dax EM, Nagel JE, Lange WR, Adler WH, Jaffe JH. Effects of nitrites on the immune system of humans, in Health hazards of nitrite inhalants, H. W. Haverkos and J. A. Dougherty (eds.) Dept. Health & Human Services, Washington, DC, 1988; 75-79.

132. Goedert JJ, Neuland CY, Wallen WC, Greene MH, Mann DL, Murray C, Strong DM, Fraumeni JF, Jr., Blattner WA. Amyl nitrite may alter T lymphocytes in homosexual men. Lancet 1982; i: 412-416.

133. Nieman RB, Fleming J, Coker RJ, Harris JR, Mitchell DM. The effect of cigarette smoking on the development of AIDS in HIV-1-seropositive individuals. AIDS 1993; 7: 705-710.

134. Lewis RJS. Food additives handbook. Van Nostrand Reinhold, New York, NY 10003, 1989.

135. Winter R. A consumer's dictionary of food additives. Crown Publishers, Inc., New York, NY 10022, 1989.

136. Mirvish SS, Williamson J, Babcook D, Sheng-Chong C. Mutagenicity of iso-butyl nitrite vapor in the Ames test and some relevant chemical properties, including the reaction of iso-butyl nitrite with phosphate. Environmental and Molecular Mutagenesis 1993; 21: 247-252.

137. National Research Council. Diet, nutrition, and cancer. National Acad. Press, Washington, D.C., 1982.

138. Newell GR, Mansell PWA, Spitz MR, Reuben JM, Hersh EM. Volatile nitrites: Use and adverse effects related to the current epidemic of the acquired immune deficiency syndrome. Am J Med 1985; 78: 811-816.

139. Cox GD. County health panel urges 'poppers' ban, cites AIDS link. The Los Angeles Daily Journal (Los Angeles) 1986: Section II, p.1, Mar. 24.

140. Haverkos HW. Nitrite inhalant abuse and AIDS-related Kaposi's sarcoma. JAIDS 1990; 3: Supplement 1, S47-S50.

141. Ratajczak HV, Thomas PT, House RV, Gaworski CL, Sherwood RL, Luster MI, Hagen KL, Abdo K, Jackson CD, Roycroft J, Aranyi C. Local versus Systemic Immunotoxicity of Isobutyl Nitrite Following Subchronic Inhalation Exposure of Female B6C3F1 Mice. Fundamental and Applied Toxicology 1995; 27: 177-184.

142. Pink Paper. Shops on their guard after poppers sale legal setback. The Pink Paper (London) 1996: June 28.

143. Seligmann M, Chess L, Fahey JL, Fauci AS, Lachmann PJ, L'Age-Stehr J, Ngu J, Pinching AJ, Rosen FS, Spira TJ, Wybran J. AIDS—an immunologic reevaluation. N Engl J Med 1984; 311: 1286-1292.

144. Lauritsen J, Wilson H. Death Rush, Poppers and AIDS. Pagan Press, New York, 1986.

145. Moss AR. AIDS and intravenous drug use: the real heterosexual epidemic. Br Med J 1987; 294: 389-390.

146. Kolata G. New picture of who will get AIDS is dominated by addicts. New York Times (New York) 1995: Sect. C, p3, February 28.

147. Furman PA, Fyfe JA, St Clair M, Weinhold K, Rideout JL, Freeman GA, Nusinoff-Lehrman S, Bolognesi DP, Broder S, Mitsuya H, Barry DW. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. PNAS 1986; 83: 8333-8337.

148. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedon JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, King D, the AZT Collaborative Working Group. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317: 185-191.

149. Kolata G. Imminent marketing of AZT raises problems; Marrow suppression hampers AZT use in AIDS victims. Science 1987; 235: 1462-1463.

150. Kramer L. A good news/bad new AIDS joke. New York Times (New York) 1996: 26, Sunday, July 14.

151. Nussbaum B. Good Intentions: How Big Business, Politics, and Medicine are Corrupting the Fight Against AIDS. Atlantic Monthly Press, New York, 1990.

152. Physicians' Desk Reference. Retrovir. Medical Economics Co., Orandell, NJ, 1994.

153. Mansuri MM, Hitchcock MJM, Buroker RA, Bregman CL, Ghazzouli I, Desiderio JV, Starrett JE, Sterzycki RZ, Martin JC. Comparison of in vitro biological properties and mouse toxicities of three thymidine analogs active against human immunodeficiency virus. Antimicrobial Agents and Chemotherapy 1990; 34: 637-641.

154. Lemaître M, Guetard D, Henin Y, Montagnier L, Zerial A. Protective activity of tetracycline analogs against the cytopathic effect of the human immunodeficiency viruses in CEM cells. Res Virol 1990; 141: 5-16.

155. Avramis VI, Markson W, Jackson RL, Gomperts E. Biochemical pharmacology of zidovudine in human T-lymphoblastoid cells (CEM). AIDS 1989; 3: 417-422.

156. Sommadossi J-P, Zhu Z, Carlisie R, Xie M-Y, Weidner DA, El Kouni MH. Novel pharmacological approaches to the treatment of AIDS and potential use of uridine phosphorylase inhibitors, in Advances in Chemotherapy of AIDS, R. B. Diasio and J.-P. Sommadossi (eds.) Pergamon Press Inc., New York, 1990; 63-73.

157. Inoue T, Tsushita K, Itoh T, Ogura M, Hotta T, Saneyoshi M, Yoshida S, Saitoh H, Tomoda Y, Nagai Y. In vitro bone marrow toxicity of nucleoside analog against human immunodeficiency virus. Antimicrob Agents Chemother 1989; 33: 576-579.

158. Gogu SR, Beckman BS, Agrawal KC. Anti-HIV drugs: Comparative toxicities in murine fetal liver and bone marrow erythroid progenitor cells. Life Sci 1989; 45: iii-vii.

159. Chiu D, Duesberg P. The Toxicity of Azidothymidine (AZT) on Human and Animal Cells in Culture at Concentrations Used for Antiviral Therapy. Genetica 1995; 95: 103-109.

160. Seligmann M, Warrell DA, Aboulker J-P, Carbon C, Darbyshire JH, Dormont J, Eschwege E, Girling DJ, James DR, Levy J-P, Peto PTA, Schwarz D, Stone AB, Weller IVD, Withnall R, Gelmon K, Lafon E, Swart AM, Aber VR, Babiker AG, Lhoro S, Nunn AJ, Vray M. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-881.

161. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH, Jr., Reichman RC, Bartlett JA, Hirsch MS, Murphy RL, Hardy WD, Soeiro R, Fischl MA, Bartlett JG, Merigan TC, Hyslop NE, Richman DD, Valentine FT, Corey L, the AIDS Clinical Trial Group of the National Insitute of Allergy and Infectious Disease. Zidovudine in asymptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322: 941-949.

162. Mir N, Costello C. Zidovudine and bone marrow. Lancet 1988; ii: 1195-1196.

163. Dournon E, Matheron S, Rozenbaum W, Gharakhanian S, Michon C, Girard PM, Perrone C, Salmon D, DeTruchis P, Leport C, the Claude Bernard Hospital AZT Study Group. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet 1988; ii: 1297-1302.

164. van Leeuwen R, van den Hurk PJ, Jöbis GJ, van der Wouw PA, Reiss P, Eeftinck Schattenkerk JKM, Danner SA, Lange JMA. Failure to maintain high-dose treatment regimens during long-term use of zidovudine in patients with symptomatic human immunodeficiency virus type 1 infection. Genitourin Med 1990; 66: 418-422.

165. Swanson CE, Cooper DA, the Australian Zidovudine Study Group. Factors influencing outcome of treatment with zidovudine of patients with AIDS in Australia. AIDS 1990; 4: 749-757.

166. Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR, Dickinson GM, Drusano GL, Egorin MJ, George WL, Gordin FM, the Veterans Affairs Cooperative Study Group on AIDS Treatment. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. N Engl J Med 1992; 326: 437-443.

167. Horwitz JP, Chua J, Noel M. Nucleosides.V. The monomesylates of 1-(2'-deoxy-beta-D-lyxofuranosyl)thymidine. J Org Chem 1964; 29: 2076.

168. Schnittman SM, Psallidopoulos MC, Lane HC, Thompson L, Baseler M, Massari F, Fox CH, Salzman NP, Fauci A. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science 1989; 245: 305-308.

169. Duesberg P, Bialy H. Duesberg and the Right of Reply According to Maddox - Nature, in AIDS: Infectious or Not?, P. Duesberg (eds.) Kluwer, Dordrecht, 1995;

170. Ascher MS, Sheppard HW, Anderson RW, Krowka JF, Bremermann HJ. Paradox remains. Nature 1995; 375: 196.

171. Lauritsen J. Poison by Prescription—The AZT Story. Asklepios Press, New York, 1990.

172. Wyatt EA. Rushing to Judgement. Barron's 1994; 23-27, August, 15.

173. Hall CT. AIDS advances boost drugmaker. San Francisco Chronicle (San Francisco) 1996: E1-E2, August 1.

174. Day M. Hype, hope and HIV. New Scientist 1996; 151: 28-31.

175. Rasnick D. Inhibitors of HIV protease useless against AIDS because HIV doesn't cause AIDS. Reappraising AIDS 1996; 4: 1-4.

176. Altman L. Scientists display substantial gains in AIDS treatment. New York Times (New York) 1996: 1A, July 11.

177. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, Shaw GM. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-122.

178. Wain-Hobson S. Virological mayhem. Nature 1995; 373: 102.

179. Duesberg PH, Schwartz JR. Latent viruses and mutated oncogenes: no evidence for pathogenicity. Progress in Nucleic Acid Research and Molecular Biology 1992; 43: 135-204.

180. Tanaka M. Abrams cautious on use of new AIDS drugs. Synapse 1996; 41: 1,5.

181. Continuum. Drugs Boost. Continuum 1996; 4: 3, July/August.

182. Selik RM, Buehler JW, Karon JM, Chamberland ME, Berkelman RL. Impact of the 1987 revision of the case definition of acquired immune deficiency syndrome in the United States. J AIDS 1990; 3: 73-82.

183. Darby SC, Ewart DW, Giangrande PLF, Dolin PJ, Spooner RJD, Rizza CR, on behalf of the UK Haemophilia Centre Directors' Organisation. Mortality before and after HIV infection in the complete UK population of haemophiliacs (letter). Nature 1995; 377: 79-82.

184. The Lancet. Zidovudine for mother, fetus, and child: hope or poison? Lancet 1994; 344: 207-209.

185. Cotton P. Trial Halted After Drug Cuts Maternal HIV Transmission Rate By Two Thirds. JAMA 1994; 271: 807.

186. Gill PS, Harrington WJ, Kaplan MH, Ribeiro RC, Bennett JM, Liebmann HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. NEJM 1995; 332: 1744-1748.

187. Continuum. Clever drug or is it the marketing? Continuum 1995; 3: 2, November/December.

188. Potts M. Non-surgical abortion: who's for methotrexate. Lancet 1995; 346: 655-656.

189. Bethell T. The Cure that Failed. National Review 1993; 33-36, May 10.

190. Greenblatt RM, Hollander H, McMaster JR, Henke CJ. Polypharmacy among patients attending an AIDS clinic: utilization of prescribed, unorthodox, and investigational treatments. Journal of Acquired Immune Deficiency Syndromes 1991; 4: 136-143.

191. Kramer L. Checking in, my chart. POZ 1994; 92-93, August/September.

192. Tuller D. Uncertain life after certain death. San Francisco Chronicle (San Francisco) 1996: 1-5 zone 6, November 24.

193. Grubman S, Gross E, Lerner-Weiss N, Hernandez M, McSherry GD, Hoyt LG, Boland M, Oleske JM. Older Children and Adolescents Living with Perinatally Acquired Human Immunodeficiency Virus Infection. Pediatrics 1995; 95: 657-663.

194. Merck Research Laboratories. The Merck Manual of Diagnosis and Therapy. Merck & Co., Inc., Rahway, NJ, 1992.

195. Freiman JP, Helfert KE, Hamrell MR, Stein DS. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 1993; 7: 379-385.

196. McLeod GX, Hammer SM. Zidovudine: Five Years Later. Annals of Internal Medicine 1992; 117: 487-501.

197. Parker WB, Cheng YC. Mitochondrial Toxicity of Antiviral Nucleoside Analogs. The Journal of NIH Research 1994; 6: 57-61.

198. Pluda JM, Yarchoan R, Jaffe ES, Feuerstein IM, Solomon D, Steinberg S, Wyvill KM, Raubitschek A, Katz D, Broder S. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann Intern Med 1990; 113: 276-282.

199. Aboulker J-P, Swart AM. Preliminary analysis of the Concorde trial. The Lancet 1993; 341: 889-890.

200. Kumar RM, Hughes PF, Khurranna A. Zidovudine Use in Pregnancy: A Report on 104 Cases and the Occurence of Birth Defects. Journal of Acquired Immune Deficiency Syndromes 1994; 7: 1034-1039.

201. Saah AJ, Hoover DR, Peng Y, Phair JP, Visscher B, Kingsley LA, Schrager LK, for the Multicenter AIDS Cohort Study. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. JAMA 1995; 273: 1197-1202.

202. Lenderking WR, Gelber RD, Cotton DJ, Cole BF, Goldhirsch A, Volberding PA, Testa MA. Evaluation of the quality of life associated with Zidovudine treatment in asymptomatic Human Immunodeficiency Virus infection. N Engl J Med 1994; 330: 738-743.

203. Poznansky MC, Coker R, Skinner C, Hill A, Bailey S, Whitaker L, Renton A, Weber J. HIV positive patients first presenting with an AIDS defining illness: characteristics and survival. British Medical Journal 1995; 311: 156-158.

204. Goedert JJ, Cohen AR, Kessler CM, Eichinger S, Seremetis SV, Rabkin CS, Yellin FJ, Rosenberg PS, Aledort LM. Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Lancet 1994; 344: 791-792.

205. Moye J, Rich KC, Kalish LA, Sheon AR, Diaz C, Cooper ER, Pitt J, Handelsman E, for the Women and Infants Transmission Study Group. Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. The Journal of Pediatrics 1996; 128: 58-67.

206. Pennisi E, Cohen J. Eradicating HIV from a patient: not just a dream? Science 1996; 272: 1884.

207. Douglas RGJ. Antimicrobial Agents, in The Pharmacological Basis of Therapeutics, Alfred, Goodman, Gilman and et al. (eds.) Pergamon Press, New York, 1990; 1182.

208. Jacobson MA, de Miranda P, Gordon SM, et al. Prolonged pancytopenia due to combined ganciclovir and zidovuduine therapy. J Infect Dis 1988; 158: 489-490.

209. Fogelman I, Lim L, Bassett R, Volberding P, Fischl MA, Stanley K, Cotton DJ, for the AIDS Clinical Trials Group. Prevalence and patterns of use of concomitant medications among participants in three multicenter human immunodeficiency virus type 1 clinical trials. Journal of Acquired Immune Deficiency Syndromes 1994; 7: 1057-1063.

210. Leland J. The end of AIDS? Newsweek 1996; 64-73, December 2.

211. Ottoboni A. Dose makes the poison. Van Nostrand & Reingold/ Int. Tompson Publishing, 1991.

212. Fenner F, McAuslan BR, Mims CA, Sambrook J, White DO. The Biology of Animal Viruses. Academic Press, Inc., New York, 1974.

213. Krieger T, Caceres CA. Wall Street Journal 1985: October 24.

214. Mathur-Wagh U, Enlow RW, Spigland I, Winchester RJ, Sacks HS, Rorat E, Yancovitz SR, Klein MJ, William DC, Mildwan D. Longitudinal study of persistent generalized lymphadenopathy in homosexual men: Relation to acquired immunodeficiency syndrome. Lancet 1984; i: 1033-1038.

215. Marmor M, Friedman-Kien AE, Laubenstein L, Byrum RD, William DC, D'Onofrio S, Dubin N. Risk factors for Kaposi's sarcoma in homosexual men. Lancet 1982; i: 1083-1087.

216. Newell GR, Mansell PWA, Wilson MB, Lynch HK, Spitz MR, Hersh EM. Risk factor analysis among men referred for possible acquired immune deficiency syndrome. Preventive Med 1985; 14: 81-91.

217. Haverkos HW, Pinsky PF, Drotman DP, Bregman DJ. Disease manifestation among homosexual men with acquired immunodeficiency syndrome: a possible role of nitrites in Kaposi's sarcoma. J Sex Trans Dis 1985; 12: 203-208.

218. Rappoport J. AIDS INC. Human Energy Press, San Bruno, CA, 1988.

219. Fettner AG, Check WA. The Truth about AIDS: Evolution of an Epidemic. Holt, Rinehart and Wilson, New York, 1985.

220. Oppenheimer GM. Causes, cases, and cohorts: The role of epidemiology in the historical construction of AIDS, in AIDS: The Making of a Chronic Disease, E. Fee and D. M. Fox (eds.) University of California Press, Berkeley, 1992; 49-83.

221. Lang S. HIV and AIDS: Have we been misled? Questions of scientific and journalistic resposibility, in AIDS: virus or drug-induced?, P. Duesberg (eds.) Kluwer, Academic publishers, Dordrecht, The Netherlands/Boston/London, 1996; 241-270.

222. Craddock M. A critical appraisal of the Vancouver men's study; does it refute the drugs/AIDS hypothesis?, in AIDS: virus or drug-induced, P. H. Duesberg (eds.) Kluwer Academic Publishers, Dordrecht, Netherland, 1996; 105-110.

223. Duesberg P. Aetiology of AIDS. Lancet 1993; 341: 1544.

224. Centers for Disease Control. Update: Outbreak of Ebola viral hemorrhagic fever Zaire, 1995. Morb Mort Weekly Reports 1995; 44: 399.

225. Duesberg P. The Duesberg-Phenomenon: Duesberg and Other Voices (letter). Science 1995; 267: 313.

226. Ward JW, Bush TJ, Perkins HA, Lieb LE, Allen JR, Goldfinger D, Samson SM, Pepkowitz SH, Fernando LP, Holland PV, Kleinman SH, Grindon AJ, Garner JL, Rutherford GW, Holmberg SD. The natural history of transfusion-associated infection with human immunodeficiency virus. N Engl J Med 1989; 321: 947-952.

227. Centers for Disease Control and Prevention. U.S. HIV and AIDS cases reported through June 1994, Mid-Year Edition. HIV/AIDS Surveillance Report 1994; 6: 1-27.

228. Centers for Disease Control. Update: acquired immunodeficiency syndrome—United States. Morbidity and Mortality Weekly Reports 1985; 34: 245-248.

229. Haverkos HW, Drotman DP. Measuring inhalant nitrite exposure in gay men: implications for elucidating the etiology of AIDS-related Kaposi's sarcoma. Genetica 1995; 95: 157-164.

230. National Institute on Drug Abuse. Annual Emergency Room Data 1990. 1990;

231. Mok JQ, De Rossi A, Ades AE, Giaquinto C, Grosch-Woerner I, Peckham CS. Infants born to mothers seropositive for human immunodeficiency virus. Lancet 1987; i: 1164-1168.

232. European Collaborative Study. Children born to women with HIV-1 infection: natural history and risk of transmission. Lancet 1991; 337: 253-260.

233. Rodriguez EM, Mofenson LM, Chang B-H, Rich KC, Fowler MG, Smeriglio V, Landesman S, Fox HE, Diaz C, Green K, Hanson IC, for the Women and Infants Transmission Study. Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. AIDS 1996; 10: 273-282.

234. Irwin DH, Kaplan LD. Pulmonary manifestations of acquired immunodeficiency syndrome-associated malignancies. Seminars in Respiratory Infections 1993; 8: 139-148.

235. Gill PS, Akli B, Coletti P, Rarick M, Louriero C, Bernstein-Singer M, Krailo M, M. LA. Pulmonary Kaposi's sarcoma: clinical findings and results of therapy. Am J Med 1989; 87: 57-61.

236. Meduri GU, Stover DE, Lee M, Myskowski PL, Caravelli JF, Zama MB. Pulmonary Kaposi's sarcoma in the acquired immune deficiency syndrome: clinical, radiographic, and pathologic manifestations. Am J Med 1986; 81: 11-18.

237. Sloand E, Kumar PN, Pierce PF. Chemotherapy for patients with pulmonary Kaposi's sarcoma: benefit of filgrastim (G-CSF) in supporting dose administration. Southern Medical Journal 1993; 86: 1219-1224.

238. Garay SM, Belenko M, Fazzini E, Schinella R. Pulmonary manifestations of Kaposi's sarcoma. Chest 1987; 91: 39-43.

239. Kaposi M. Idiopathisches multiples Pigmentsarkom der Haut. Archiv für Dermatologie und Syphilis 1872; 2: 265-273.

240. Drotman DP, Haverkos H. What Causes Kaposi's Sarcoma? Inquiring Epidemiologists Want to Know. Epidemiology 1992; 3: 191-193.

241. Toufexis A. Innocent victims. Time 1991; 137: 56-60,

242. Schuster CR. Foreword, in Cocaine: Pharmacology, Effects and Treatment of Abuse, J. Grabowski (eds.) National Institute on Drug Abuse, Washington, DC, 1984; VII-VIII.

243. Savona S, Nardi MA, Lenette ET, Karpatkin S. Thrombocytopenic purpura in narcotics addicts. Ann Intern Med 1985; 102: 737-741.

244. Donahoe RM, Bueso-Ramos C, Donahoe F, Madden JJ, Falek A, Nicholson JKA, Bokos P. Mechanistic implications of the findings that opiates and other drugs of abuse moderate T-cell surface receptors and antigenic markers. Annals of the New York Academy of Sciences 1987; 496: 711-721.

245. Espinoza P, Bouchard I, Buffet C, Thiers V, Pillot J, Etienne JP. High prevalence of infection by hepatitis B virus and HIV in incarcerated French drug addicts. Gastroenterologie Clinique et Biologique 1987; 11: 288-292.

246. Weber R, Ledergerber W, Opravil M, Siegenthaler W, Lüthy R. Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. Br Med J 1990; 301: 1362-1365.

247. Associated Press. Study Finds Ex-Smokers Still Risk Lung Cancer. San Francisco Chronicle (San Francisco) 1995: A5, May 23.

248. Cohen J. New clues found to how some people live with HIV. Science 1995; 270: 917-918.

249. Learmont J, Tindall B, Evans L, Cunningham A, Cunningham P, Wells J, Penny R, Kaldor J, Cooper DA. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 1992; 340: 863-867.

250. McCarthy M. Attenuated HIV-1 strains share gene deletyions. Lancet 1995; 346: 1357.

251. Cao Y, Quin L, Zhang L, Safrit J, Ho DD. Virologic and Immunologic Characterization of Long-Term Survivors of Human Immunodeficiency Virus Type 1 Infection. N Engl J Med 1995; 332: 201-208.

252. Munoz A. Disease progression 15 percent of HIV-infected men will be long-term survivors. AIDS Weekly, (News Report) 1995; May, 15 & 29: 5-6 & 3-4.

253. Gavzer B. Love has Helped Keep me Alive. Parade Magazine 1995; 4-6, April 16.

254. Wells J. We have to question the so-called 'facts'. Capital Gay 1993: 14-15, August 20th.

255. Root-Bernstein RS. Five myths about AIDS that have misdirected research and treatment. Genetica 1995; 95: 111-132.

256. Callen M. Surviving AIDS. HarperPerennial, New York, 1990.

257. Gorman C. Time 1993; 49, 22 March.

258. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, Montefiori D, Orenstein JM, Fox C, Schrager LK, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332: 209-216.

259. Munoz A, Kirby AJ, He YD, Margolick JB, Visscher BR, Rinaldo CR, Kaslow RA, Phair JP. Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995; 8: 496-505.

260. Hoover DR, Rinaldo C, He Y, Phair J, Fahey J, Graham NM. Long-term survival without clinical AIDS after CD4+ cell counts fall below 200 x 10 (6)/1. AIDS 1995; 9: 145-152.

261. Hogervorst E, Jurriaans S, De Wolf F, Van Wijk A, Wiersma A, Valk M, Roos M, Van Gemen B, Coutinho R, Miedema F, et al. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. Journal of Infectious Diseases 1995; 171: 811-821.

262. Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M, Miralles GD, Fauci AS. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. Journal of Infectious Diseases 1996; 173: 60-67.

263. Harrer T, Harrer E, Kalams SA, Elbeik T, Staprans SI, Feinberg MB, Cao Y, Ho DD, Yilma T, Caliendo AM, et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. Aids Research and Human Retroviruses 1996; 12: 585-592.

264. Garbulgia AR, Salvi R, Dicaro A, Cappiello G, et al. In vitro activation of HIV RNA expression in peripheral blood lymphocytes as a marker to predict the stability of non-progressor status in long-term survivors. AIDS 1996; 10: 17-21.

265. Baltimore D. Lessons from people with nonprogressive HIV infection (editorial; comment). N Engl J Med 1995; 332: 259-260.

266. Hand TH. Antiviral Drugs versus Long-Term Survival; Why antiviral drugs cannot resolve AIDS. Reappraising AIDS 1996; 4: 1-4.

267. Maddox J. Rage and confusion hide role of HIV. Nature 1992; 357: 188-189.

268. Simmons T. Living on the edge. The Advocate 1995; December: 25-28, December 26.

269. Merson MH. Slowing the spread of HIV: Agenda for the 1990's. Science 1993; 260: 1266-1268.

270. World Health Organization. The current Global Situation of the HIV/AIDS Pandemic. 1995;

271. Strathdee SA, Craib KJP, Hogg RS, M. OS, Montaner J, Schechter MT. Long-term non-progression in HIV infection. Lancet 1995; 346: 1372.

272. Cocchi F, DeVico A, Grazino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of Rabntes, Mip-1a, and Mip-1b as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270: 1811-1815.

273. Lang W, Perkins H, Anderson RE, Royce R, Jewell N, Winkelstein W, Jr. Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. JAIDS 1989; 2: 63-69.

274. Lang W, Anderson RE, Perkins H, Grant RM, Lyman D, Winkelstein W, Royce R, Levy JA. Clinical, Immunologic, and Serologic Findings in Men at Risk for Acquired Immunodeficiency Syndrome. JAMA 1987; 257: 326-330.

275. Ellison BJ, Downey AB, Duesberg PH. HIV as a surrogate marker for drug-use: a re-analysis of the San Francisco Men's Health Study. Genetica 1995; 95: 165-171.

276. Marion SA, Schechter MT, Weaver MS, McLeod WA, Boyko WJ, Willoughby B, Douglas B, Craib KJP, O'Shaughnessy M. Evidence that prior immune dysfunction predisposes to human immunodeficiency virus infection in homosexual men. JAIDS 1989; 2: 178-186.

277. Archibald CP, Schechter MT, Le TN, Craib KJP, Montaner JSG, O'Shaughnessy MV. Evidence for a sexually transmitted cofactor for AIDS-related Kaposi's sarcoma in a cohort of homosexual men. Epidemiology 1992; 3: 203-209.

278. Kaslow RA, Phair JP, Freidman HB, Lyter RE, Solomon RE, Dudley J, Polk F, Blackwelder W. Infection with the Human Immunodeficiency Virus: clinical manifestations and their relationship to immunodeficiency. Ann Intern Med 1987; 107: 474-480.

279. Ostrow DG, Van Raden MJ, Fox R, Kingsley LA, Dudley J, Kaslow RA, the Multicenter AIDS Cohort Study (MACS). Recreational drug use and sexual behavior change in a cohort of homosexual men. AIDS 1990; 4: 759-765.

280. Phair J, Jacobson L, Detels R, Rinaldo C, Saah A, Schrager L, Munoz A. Acquired immune deficiency syndrome occuring within 5 years of infection with human immunodeficiency virus type-1: The multicenter AIDS cohort study. J Acquired Immune Deficiency Syndromes 1992; 5: 490-496.

281. Parke D. Key factor. The Sunday Times (London) 1993: letter, Dec. 19.

282. Seidman SN, Rieder RO. A Review of Sexual Behaviour in the United States. The American Journal of Psychiatry 1994; 151: 330-341.

283. Des Jarlais DC, Friedman SR, Marmor M, Mildvan D, Yancovitz S, Sotheran JL, Wenston J, Beatrice S. CD4 Lymphocytopenia among injecting drug users in New York City. J Acquir Immune Defic Syndr 1993; 6: 820-822.

284. Nicolosi A, Musico M, Saracco A, Molinari S, Ziliani N, Lazzarin A. Incidence and risk factors of HIV infection: A prospective study of seronegative drug users from Milan and Northern Italy, 1987-1989. Epidemiology 1990; 1: 453-459.

285. Moore PS, Chang Y. Detection of Herpesvirus-like DNA Sequences in Kaposi's Sarcoma in Patients With and Those Without HIV Infection. N Engl J Med 1995; 332: 1181-1185.

286. Weiss SH, Weston Klein C, Mayur RK, Besra J, Denny TN. Idiopathic CD4+ T-lymphocytopenia. Lancet 1992; 340: 608-609.

287. Gottlieb MS, Schanker HM, Fan PT, Saxon A, Weisman JD, Pozalski J. Pneumocystis pneumonia—Los Angeles. Morbidity and Mortality Weekly Reports 1981; 30: 250-252.

288. Haverkos HW. Kaposi's sarcoma and nitrite inhalants, in Psychological, Neuropsychiatric and Substance Abuse Aspects of AIDS, T. P. Bridge, H. Heather and M. Johnson (eds.) Raven Press, New York, 1988; 165-172.

289. van Griensven GJP, Vroome EMM, de Wolf H, Goudsmit J, Roos M, Coutinho RA. Risk factors for progression of human immunodeficiency virus (HIV) infection among seroconverted and seropositive homosexual men. Am J Epidemiol 1990; 132: 203-210.

290. Graham NMH, Zeger SL, Park LP, Phair JP, Detels R, Vermund SH, Ho M, Saah AJ, Multicenter AIDS Cohort Study. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. Lancet 1991; 338: 265-269.

291. Seage GR, Mayer KH, Horsburgh CR, Holmberg SD, Moon MW, Lamb GA. The relation between nitrite inhalants, unprotected receptive anal intercourse, and the risk of human immunodeficiency virus infection. J Am Epidemiol 1992; 135: 1-11.

292. Winkelstein W, Jr., Lyman DH, Padian N, Grant R, Samuel M, Wiley JA, Anderson RE, Lang W, Riggs J, Levy JA. Sexual practices and risk of infection by the human immunodeficiency virus: The San Francisco men's health study. JAMA 1987; 257: 321-325.

293. Lemp GF, Payne SF, Rutherford GW, Hessol NA, Winkelstein W, Jr., Wiley JA, Moss AR, Chaisson RE, Chen RT, Feigal DW, Thomas PA, Werdegar D. Projections of AIDS morbidity and mortality in San Francisco. J Am Med Assoc 1990; 263: 1497-1501.

294. Mathur-Wagh U, Mildvan D, Senie RT. Follow-up of 4 1/2 years on homosexual men with generalized lymphadenopathy. NEJM 1985; 313: 1542-1543.

295. San Francisco Department of Public Health, Lesbian & Gay Substance Abuse Planning Group. Gay Men, Lesbians and their Alcohol and Other Drug Use: A Review of the Literature. 1991 September;

296. Selik RM, Starcher ET, Curran JW. Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS 1987; 1: 175-182.

297. Friedman-Kien AE, Saltzman BR, Cao Y, Nestor MS, Mirabile M, Li JJ, Peterman TA. Kaposi's sarcoma in HIV-negative homosexual men. Lancet 1990; 335: 168-169.

298. Safai B, Peralta H, Menzies K, Tizon H, Roy P, Flomberg N, Wolinsky S. Kaposi's sarcoma among HIV-negative high risk population. VII International Conference on AIDS. 1991;

299. Anonymous. Patient accuses Kaiser. Oakland Tribune 1992; December 1.

300. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM. Is a positive Western blot proof of HIV infection? Biotechnology 1993; 11: 696-707.

301. Johnson, C., Zenger's magazine, California. Sept. 1996. Factors known to cause false-positie HIV antibody test results. Continuum (London) 1996; 4: 5,

302. Cohen J. Is a new virus the cause of KS? Science 1994; 266: 1803-1804.

303. Ascher MS, Sheppard HW, Winkelstein Jr. W. AIDS-associated Kaposi's sarcoma (letter). Science 1995; 267: 1080.

304. Selwyn PA, Feingold AR, Hartel D, Schoenbaum EE, Adderman MH, Klein RS, Freidland SH. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS 1988; 2: 267-272.

305. Braun MM, Truman BI, Maguire B, Di Ferdinando GT, Jr., Wormser G, Broaddus R, Morse DL. Increasing incidence of tuberculosis in a prison inmate population, associated with HIV-infection. J Am Med Assoc 1989; 261: 393-397.

306. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. JAMA 1987; 258: 1143-1154.

307. Annell A, Fugelstad A, Ågren G. HIV-prevalence and mortality in relation to type of drug abuse among drug addicts in Stockholm 1981-1988, in Drug Addiction and AIDS, N. Loimer, R. Schmid and A. Springer (eds.) Springer-Verlag, New York, 1991; 16-22.

308. Püschel K, Mohsenian F. HIV-1-prevalence among drug deaths in Germany, in Drug Addiction and AIDS, N. Loimer, R. Schmid and A. Springer (eds.) Springer-Verlag, New York, 1991; 89-96.

309. Bschor F, Bornemann R, Borowski C, Schneider V. Monitoring of HIV-spread in regional populations of injecting drug users—the Berlin experience, in Drug Addiction and AIDS, N. Loimer, R. Schmid and A. Springer (eds.) Springer-Verlag, New York, 1991; 102-109.

310. Mientjes GH, Miedema F, van Ameijden EJ, van den Hoek AA, Schellekens PTA, Roos MT, Coutinho RA. Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users. AIDS 1991; 5: 35-41.

311. Des Jarlais DC, Friedman SR, Hopkins W. Risk reduction of the acquired immunodeficiency syndrome among intravenous drug users, in AIDS and IV Drug Abusers: Current Perspectives, R. P. Galea, B. F. Lewis and L. Baker (eds.) National Health Publishing, Owings Mills, MD, 1988; 97-109.

312. Brudney K, Dobkin J. Resurgent tuberculosis in New York City. Am Rev Respir Dis 1991; 144: 744-749.

313. Koch T. Uninfected children of HIV-infected mothers may still suffer nervous problems. CDC AIDS Weekly 1990; 9, July 30.

314. Aylward EH, Butz AM, Hutton N, Joyner ML, Vogelhut JW. Cognitive and motor development in infants at risk for human immunodeficiency virus. AJDC 1992; 146: 218-222.

315. Rogers MF, Ou C-Y, Rayfield M, Thomas PA, Schoenbaum EE, Abrams E, Krasinski K, Selwyn PA, Moore J, Kaul A, Grimm KT, Bamji M, Schochetman G, the New York City Collaborative Study of Maternal HIV Transmission, Montefiori Medical Center HIV Perinatal Transmission Study Group. Use of the polymerase chain reaction for early detection of the proviral sequences of human immunodeficiency virus in infants born to seropositive mothers. NEJM 1989; 320: 1649-1654.

316. Culver KW, Ammann AJ, Patridge JC, Wong DF, Wara DW, Cowan MJ. Lymphocyte abnormalities in infants born to drug-abusing mothers. J Pediatr 1987; 111: 230-235.

317. Scolaro M, Durham R, Pieczenik G. Potential molecular competitor for HIV. Lancet 1991; 337: 731-732.

318. Till M, MacDonnell KB. Myopathy with human immunodeficiency virus type 1 (HIV-1) infection: HIV-1 or zidovudine? Ann Intern Med 1990; 113: 492-494.

319. Gill PS, Rarick M, Byrnes RK, Causey D, Loureiro C, Levine AM. Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1987; 107: 502-505.

320. Freeman E. HIV does not cause AIDS. HealthQuest 1996; 35-49, Fall 1996.

321. Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, Volberding PA. Within-Subject Variation in CD4 Lymphocyte Count in Asymptomatic Human Immunodeficiency Virus Infection: Implications for Patient Monitoring. J Infectious Diseases 1994; 169: 28-36.

322. Blanche S, Mayaux M-J, Rouzioux C, Teglas J-P, Firtion G, Monpoux F, Ciraru-Vigneron N, Meier F, Tricoire J, Courpotin C, Vilmer E, Griscelli C, Delfraissy J-F, The French Pediatric HIV Infection Study Group. Relation of the Course of HIV Infection in Children to the Severity of the Disease in their Mothers at Delivery. The New England Journal of Medicine 1994; 330: 308-312.

323. The European Collaborative Study. Natural History of Vertically Acquired Human Immunodeficiency Virus-1 Infection. Pediatrics 1994; 94: 815-819.

324. Friedman SR, Jose B, Deren S, Des Jarlais DC, Neaigus A. Risk Factors for Human Immunodeficiency Virus Seroconversion among Out-of-Treatment Drug Injectors in High and Low Seroprevalence Cities. American Journal of Epidemiology 1995; 142: 864-874.

325. Evenson W. Heroin's in fashion - and death statistics prove it. San Francisco Chronicle (San Francisco) 1996: A1, A8, July 30.

326. Centers for Disease Control and Prevention. U.S. HIV and AIDS cases reported through June 1996. HIV/AIDS Surveillance Report 1996; 8: 1-33.

327. Kramer A. HIV hits former USSR a small city's story. San Francisco Chronicle (San Francisco) 1996: A1 & A11, November 26.

328. Gallo RC, Sarin PS, Gelmann EP, Robert-Guroff M, Richardson E. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983; 220: 865-867.

329. Montagnier L, Chermann JC, Barré-Sinoussi F, Chamaret S, Gruest J, Nugeyre MT, Rey F, Dauguet C, Axler-Blin C, Vézinet-Brun F, Rouzioux C, Saimot G-A, Rozenbaum W, Gluckman JC, Klatzmann D, Vilmer E, Griscelli C, Foyer-Gazengel C, Brunet JB. A new human T-lymphotropic retrovirus: Characterization and possible role in lymphadenopathy and acquired immune deficiency syndromes, in Human T-Cell Leukemia/Lymphona Virus; The Family of Human T-Lymphotropic Retroviruses: Their Role in Malignancies and Association with AIDS, R. C. Gallo, M. E. Essex and L. Gross (eds.) Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1984; 363-379.

330. Centers for Disease Control. An evaluation of the immunotoxic potential of isobutyl nitrite. MMWR 1983; 32: 457-464.

331. McKeown T. The Role of Medicine: Dream, Mirage, or Nemesis? Princeton University Press, Princeton, NJ, 1979.

332. Kolata G. Anthropologists suggest cannibalism is a myth. Science 1986; 232: 1497-1500.

333. Stolberg S. Studies rebut controversial AIDS theory. Los Angeles Times (Los Angeles) 1993: A18, March 11.

334. Perlman D. Biologist's theory on AIDS attacked. San Francisco Chronicle (San Francisco) 1993: A10, March 11.

335. Duesberg P. HIV and the aetiology of AIDS. Lancet 1993; 341: 957-958.

336. Duesberg P. AIDS Data. Science 1995; 268: 350-351.

337. Ascher M, Sheppard HW, Winkelstein W. AIDS Data. Science 1995; 268: 351-352.

338. Klimas NG, Blaney NT, Morgan RO, Chitwood D, Milles K, Lee H, Fletcher MA. Immune Function and Anti-HTLV-I/II Status in Anti-HIV-1-Negative Intravenous Drug Users Receiving Methadone. The American Journal of Medicine 1991; 90: 163-170.

339. Schechter MT, Craib KJP, Gelmon KA, Montaner JSG, Le TN, O'Shaughnessy MV. HIV-1 and the aetiology of AIDS. Lancet 1993; 341: 658-659.

340. Smith GD, Phillips AN. Confounding in epidemiological studies: why independent effects may not be all they seem. BMJ 1992; 305: 757-759.

341. Maddox J. Has Duesberg a right of reply? Nature 1993; 363: 109.

342. Koliadin V. Duesberg: rights and wrongs. Nature 1993; 364: 96.

343. Birkett N. The Duesberg phenomenon: Duesberg and other voices. Science 1995; 268: 315.

344. Farber C. AIDS Words from the Front. SPIN Magazine 1995; 189-193, 214-215, April.

345. Ostrom N. Early Intervention: An Idea Whose Time Has Gone? New York Native 1995; 35-39, August 28.

346. Ostrom N. Nightmare on AZT Street. New York Native 1995; 34-36, September 4.

347. Duesberg P. Duesberg responds (letter). The Scientist 1995: 13, September 4.

348. Kolata G. Debunking doubts that HIV causes AIDS. The New York Times (New York) 1993: A11, March 11.

349. Gutknecht G. Letter to Dr. Fauci. (Washington, D.C.) 1995: March 24.

350. AIDS Weekly. Government Congressman questions funding for AIDS research. AIDS Weekly (electronic version) 1995; May, 22:

351. Chronicle SF. California winning war on cigarette smoking. San Francisco Chronicle (San Francisco) 1996: A3, Nov. 8, 1996.

352. McCormack TP. The AIDS benefits handbook: everything you need to know to get social security, welfare, medicaid, medicare, food stamps, housing, drugs, and other benefits. Yale University Press, New Haven, 1990.